Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24933332

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2014 Aug 23
First author
Garon EB

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2014 Aug 23;384(9944):640-2. doi: 10.1016/S0140-6736(14)60895-3.
    note
    Source null
    related pmid
    24933331
    relationship
    Comment in

Authors and identifiers

  1. name
    Garon EB
    type
    Author
  2. name
    Ciuleanu TE
    type
    Author
  3. name
    Arrieta O
    type
    Author
  4. name
    Prabhash K
    type
    Author
  5. name
    Syrigos KN
    type
    Author
  6. name
    Goksel T
    type
    Author
  7. name
    Park K
    type
    Author
  8. name
    Gorbunova V
    type
    Author
  9. name
    Kowalyszyn RD
    type
    Author
  10. name
    Pikiel J
    type
    Author
  11. name
    Czyzewicz G
    type
    Author
  12. name
    Orlov SV
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Garon EB
    type
    Author
  2. name
    Ciuleanu TE
    type
    Author
  3. name
    Arrieta O
    type
    Author
  4. name
    Prabhash K
    type
    Author
  5. name
    Syrigos KN
    type
    Author
  6. name
    Goksel T
    type
    Author
  7. name
    Park K
    type
    Author
  8. name
    Gorbunova V
    type
    Author
  9. name
    Kowalyszyn RD
    type
    Author
  10. name
    Pikiel J
    type
    Author
  11. name
    Czyzewicz G
    type
    Author
  12. name
    Orlov SV
    type
    Author
bibliography ids
  1. nci-bib-2e42ecbd6285e3017cdb5a2f
book metadata
content sha256
88c4dc5fdcdcb8932abda257fb727260ffbfb6b534e91399efacaa766a47ce40
document type
citation
dois
  1. 10.1016/S0140-6736(14)60845-X
electronic publication date
display
2014 Jun 2
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:24933332
immutable id
pubmed:24933332@88c4dc5fdcdcb8932abda257fb727260ffbfb6b534e91399efacaa766a47ce40
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9944
name
Lancet (London, England)
nlm unique id
2985213R
pages
665-73
volume
384
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2014 Aug 23;384(9944):640-2. doi: 10.1016/S0140-6736(14)60895-3.
    note
    Source null
    related pmid
    24933331
    relationship
    Comment in
outcomes validated
false
pmid
24933332
provenance
batch id
69903be8ceab8801c81a
provider
NCBI PubMed ESummary
record sha256
ab997b63b848807f396c87859e9f29aa0e25d7edf67cda48fa29857a0311f783
response sha256
1e367491c3c459a93f45b3db99ca1f9293ed2287c48bdf758bb088ffcd7c96eb
retrieved at
2026-09-09T23:47:05.208886+00:00
publication date
display
2014 Aug 23
precision
day
year
2014
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/24933332/
title
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Preserved source evidence · Not medical advice